MDX-124
Advanced Solid Tumors (including Biliary Tract Cancer)
Key Facts
About Medannex
Medannex is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach to treating cancer and autoimmune diseases by targeting the protein annexin-A1. Its lead candidate, MDX-124, is a first-in-class monoclonal antibody undergoing a Phase 1b study in oncology, with preparations underway for studies in autoimmune indications. The company leverages strong academic collaborations and is led by a seasoned team with significant biotech experience, positioning itself to address significant unmet medical needs in multiple therapeutic areas.
View full company profileAbout Medannex
Medannex is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach to treating cancer and autoimmune diseases by targeting the protein annexin-A1. Its lead candidate, MDX-124, is a first-in-class monoclonal antibody undergoing a Phase 1b study in oncology, with preparations underway for studies in autoimmune indications. The company leverages strong academic collaborations and is led by a seasoned team with significant biotech experience, positioning itself to address significant unmet medical needs in multiple therapeutic areas.
View full company profile